**Nebuliser Treatment for COPD and Asthma**

|  |  |
| --- | --- |
| **Production date** | **Jan 2024** |
| **Authors** | SH  LL  VW  DL  SM |
| **Review date** |  |

Of note, the trials were always performed by the lung lab, but the team didn’t feel comfortable advising what inhalers should be stopped/started on week 3 & 4 of the trial and therefore this was passed on to the nursing team. This has added to our already expanding workload. The lung lab have been struggling with capacity issues due to staffing and it has been difficult to arrange ad hoc tests at times. We tried to streamline the process as and as the majority of patients needing a nebuliser trial have end stage COPD, we asked the wider team if we could use peak flow monitoring rather than spirometry. I know this isn’t ideal but is an objective measure. If the patient finds it beneficial to their symptoms and improves quality of life, this would be the main objective.

In reference to whether we monitor renal function, we do not as a rule. These patients are referred from secondary or primary care clinicians. In future, we could consider adding this to our letters when a patient has a successful trial and advise to monitor their renal function in those patients over 60.

On the document it says Stop Trimbow/Trelegy and use Fostair/Relvar via aerochamber. Before printing the instruction sheet for the patient, we delete the inhalers that aren’t being used, i.e. if using Trelegy/Relvar, we would delete the Trimbow/Fostair and aerochamber (we know you can’t take Ellipta via aerochamber). We don’t have a preference of aerochamber – any spacer device is encouraged and don’t discriminate against the aerochamber plus.

Patients are provided with the 4-week supply of Ventolin and Ipratropium at the clinic appointment (all patients are given 2.5mg dose and letter to GP would highlight this).

Hope this clarifies a few things.

1. In general most people are able to use an inhaler device (dry powder or pressured meter dose inhaler) or a pressured meter dose inhaler with a spacer device with adequate technique and good clinical effect. Some people (for example with a stroke, significant physical disability or memory impairment) may require nebuliser therapy as opposed to usual inhaler therapy.
2. There are a very small number of people who would benefit from nebuliser therapy in acute situations but these are rare.
3. **Risks of Nebuliser Use**

Most respiratory interested clinicians are very worried about overuse of nebulisers as there are well documented concerns:

1. Good evidence in the BTS / SIGN Asthma guidance that in all but severe / life threatening asthma (who should be clinically evaluated and often admitted) use of salbutamol pressured meter dose via spacer is equally effective as a nebuliser at a much lower dose of medication.(1)
2. Well documented that even people with hospital reviewed nebulisers and reviewed regularly have more exacerbations of COPD (by a factor of two) compared to those with similar severity who don’t – and the majority of these carefully reviewed nebulisers harbour potential pathogenic bacteria in the machine that increases this risk (cultured in research studies). The risk of infection within the nebuliser is likely to be greater in older, less well maintained nebulisers especially where hygiene has not been taught (though this has not be researched). The patient will be nebulising and inhaling potentially pathogenic bacteria along with their medication.(2-5)
3. Many people with severe respiratory disease have or at risk of cardiovascular disease. Higher doses of salbutamol and ipratropium increase the heart rate (and leave people more prone to cardiac arrhythmias). Salbutamol reduces serum potassium levels (nebulised salbutamol is commonly used to treat hyperkalaemia). Hence people using this in or outside a hospital setting should have close supervision and consideration of cardiac monitoring and close hospital supervision and monitoring need to have their cardiac and potential electrolyte imbalances considered and plans put in place to monitor pulse rate and bloods along with safety netting. (6-11)
4. There are rare reportings (but not uncommon) of allergic reactions to salbutamol and ipratropium – similarly some people have worsening breathlessness and wheeze with this treatment (though usually identified at time of emergency presentation)(11, 12)
5. Acute narrow angle glaucoma is a rare but well recognised problem with ipratropium (severe eye pain, reduced vision and often nausea)(12)
6. People with asthma who are treated with just short acting beta agonists have a higher mortality risk (not treating the underlying inflammation which is increasing) hence caution in allowing any persistent treatment of asthma with just bronchodilators.
7. People with severe COPD who are using nebulisers acutely again may have other conditions worsening their symptoms and the nebuliser will increase their heart rate, lower potassium levels and fail to manage the underlying problem.
8. **Clinicians should not initiate nebuliser therapy on the following basis:**
9. Bought at a nebuliser at car boot sale or on line from Amazon or Aldi (prescription drugs need medical evaluation as to their appropriateness)
10. A friend / relative of the patient told them it would be useful
11. Recommended by GP, nurse, pharmacist, paramedic, emergency hospital doctor or clinician

* Any clinician who has assessed the patient as suitable for long term nebuliser treatment should document this carefully (frequency of use, monitoring requirement – and when the clinician will review) – the numbers requiring nebulisers are very low and should probably all remain under specialist care. This should be in writing rather than word of mouth for clarity.

1. **Nebuliser initiated as an in patient**

* It would be very rare that respiratory specialist colleagues would initiate long term nebuliser therapy whilst an inpatient. In this situation it should be clear about the rationale in the discharge summary – and paperwork would be completed, along with teaching the patient and carers on how to use. They will be provided with information on how to use / clean the equipment.
* Follow up for replacing the loan nebuliser and annual servicing (via Medequip) along with annual consumables (from the hospital) will continue.
* Directions on use and type of nebules suggested for prescription will be clear on the discharge summary.
* If in doubt refer back to the hospital discharge team for further assessment.
* Patient discharged on a nebuliser will have at least a telephone follow up following discharge. Further follow up recommendations will be clear in hospital correspondence in the longer term and as very few benefit many of these will require specialist follow up.

1. **Temporary Nebuliser use for patients discharged to Hospital@Home**

* Temporary nebulisers use may be recommended on hospital discharge and followed up by the hospital at home team.
* The hospital home will remove the nebuliser when no longer needed. Prescriptions if required in the community will be communicated on each occasion by the H@H team
* If it appears that longer treatment may be required the patient will be referred back to the hospital respiratory team.

1. **Referral to specialist for recommendation of nebuliser**

Clinicians referring for nebuliser suitability assessment (and recognising inherent risk) should ensure there has

1. Had a clinical assessment to exclude other causes of breathlessness and that the diagnosis is right
2. The patient has been assessed for alternative inhalers

The patient will have three appointments

1. A one hour assessment
2. Telephone follow up at week 2
3. 30 minute face to face at week 4

Assuming eligible the specialist team will

1. Complete paperwork / loan agreement
2. Teach patient and family / carers on how to use
3. Provide patient information (leaflet and advise) on how to use clean equipment and possible side effects
4. Write to the Primary care team clearly identifying the rationale for benefit and advise on nebule prescriptions along with appropriate review

**Conclusion**

There are significant risks with nebuliser therapy as well as in a small number of people potential benefits. Nebulisers should be carefully initiated – and their long term maintenance and review carefully considered – our guidance is designed to help clinicians and improve patient safety.

**References**

1. British Thoracic Society, Scottish Intercollegiate Guideline Network. SIGN 158 British Guidelines for the Management of Asthma. Guideline. 2019.

2. Tang JW, Kalliomaki P, Varila TM, Waris M, Koskela H. Nebulisers as a potential source of airborne virus. Journal of Infection. 2020;81(4):647-79.

3. Jarvis S, Ind PW, Thomas C, Goonesekera S, Haffenden R, Abdolrasouli A, et al. Microbial contamination of domiciliary nebulisers and clinical implications in chronic obstructive pulmonary disease. BMJ Open Respiratory Research. 2014;1(1).

4. Alhaddad B, Smith FJ, Robertson T, Watman G, Taylor KMG. Patients’ practices and experiences of using nebuliser therapy in the management of COPD at home. BMJ Open Respiratory Research. 2015;2(1).

5. van GWH, Douma WR, Slebos DJ, Kerstjens HA. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database of Systematic Reviews [Internet]. 2016; (8). Available from: <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011826.pub2/abstract>.

6. Montassier E, Legrand M, Rossignol P, Potel G. Hyperkalemia in the emergency department: Consider the use of nebulized salbutamol. The American Journal of Emergency Medicine. 2019;37(5):1004.

7. van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting β<sub>2</sub> agonists. Thorax. 2001;56(7):529-35.

8. Reuser T, Flanagan D, Borland C, Bannerjee D. Acute angle closure glaucoma occurring after nebulized bronchodilator treatment with ipratropium bromide and salbutamol. Journal of the Royal Society of Medicine. 1992;85(8):499.

9. Whyte K, Reid C, Addis G, Whitesmith R, Reid J. Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline. British journal of clinical pharmacology. 1988;25(5):571-8.

10. Phillips P, Vedig A, Jones P, Chapman M, Collins M, Edwards J, et al. Metabolic and cardiovascular side effects of the beta 2‐adrenoceptor agonists salbutamol and rimiterol. British journal of clinical pharmacology. 1980;9(5):483-91.

11. electronic Medicines Compendium (eMC). Salbutamol Nebules (<https://www.medicines.org.uk/emc/product/10257/smpc#gref>) accessed 1/1/24. 2024.

12. electronic Medicines Compendium (eMC). Atrovent UV <https://www.medicines.org.uk/emc/product/3818/smpc#gref>. 2024.

The following will be added as appendices when agreed across the Somerset Foundation Trust footprint (in process at the moment between Musgrove Park and Yeovil Hospital teams)

Appendix 1 – How to use a nebuliser

Appendix 2 – Loan agreement with patient for use of nebuliser

Appendix 3 – The nebuliser trial pathway used in specialist care including protocols